Insider trade

CEO reported a non-open-market transaction in ROIV

Traded Dec 15, 2025 · Filed Dec 18, 2025

Roivant SciencesROIV

798K
Shares · @ $21.68

Why it stands out

Not classified as an open-market trade.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 15, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 18, 2025

CEOOther

Context

Classification

other

Code J — not an open-market trade

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001140361-25-045906
Filed / recorded

Dec 18, 2025, 7:00 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Roivant Sciences Ltd.

Issuer CIK

1635088

Ticker

ROIV

Reporting person

Matthew Gline

Relationship

Director, Officer

Officer title

CEO

Security

Common Shares

Table

Non-derivative (Table I)

Transaction date

Dec 15, 2025

Transaction code

J

Shares / units

797,595

Price per share

$21.68

Acquired / disposed

Disposed (D)

Shares owned after

17,287,081

Ownership form

Direct

Amendment

No

Footnotes from the filing

Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934.

Around the same time

200KShares · @ $3.85

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record

CEO sold ~$4.38M of Roivant Sciences

Automatic sale9mo ago

200KDerivative units

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record